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PCR ANALYSIS ON THE EFFECTS OF ALPHA SYNUCLEIN TREATMENT ON C6 RAT
GLIOMA CELLS
Michael J. Helmus, M.S.
Western Michigan University, 2019

Multiple System Atrophy (MSA) is a rare neurological disease that mainly
implicates the neuronal protein, alpha synuclein, as being centrally involved in MSA
pathology. Despite synucleinopathy dogma, little is known about alpha synucleins role in
MSA pathogenesis. The Ide laboratory previously conducted an Affymetrix gene
expression study utilizing the post-mortem pons tissue from eight individuals with MSA
and five individuals without any known neurological disorders. One conclusion from that
study was that downregulation of numerous mitochondrial homeostasis related genes
had occurred. It is hypothesized that alpha synuclein can perturb mitochondrial
homeostasis through direct interaction with mitochondria. This study utilized Reverse
Transcriptase PCR and Droplet Digital PCR to confirm downregulation of the mitophagy
related gene, Bnip3, that was observed in the MSA Affymetrix study, when C6 rat glioma
cells were treated with a single dose of human wild type alpha synuclein. qPCR and
ddPCR was then used to assess the impact of alpha synuclein treatment on
mitochondrial genome copy numbers, which served as a surrogate measure of
mitochondrial number, and the single copy nuclear-encoded gene, Beta Actin. Detection
of mtDNA and Beta Actin was decreased at all time points assessed. This study
demonstrates that a single treatment of alpha synuclein resulted in decreased detection
of mitochondrial genomes per cell, which offers potential insight into synucleinopathy
pathogenesis.
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CHAPTER 1
INTRODUCTION
Overview and History
Multiple System Atrophy (MSA) is a rare neurological disease that is poorly
understood by the medical and scientific community. Typically occurring in an
individual’s sixth decade of life, MSA progresses rapidly and presents with a variety of
autonomic failures and eventually, complete loss of motor control after only a few years
after onset. MSA is one of the lesser known synucleinopathies and shares many
similarities with Parkinson’s Disease and Dementia with Lewy Bodies. The
synucleinopathies implicate involvement of the neuronal protein, alpha synuclein, and
the toxic accumulation of aggregated and fibrillated alpha synuclein in different cell types
and regions of the brain give rise to these pathologically distinct diseases. In MSA, alpha
synuclein traffics to the cytoplasm of oligodendrocytes, disrupting their essential role in
neuronal maintenance and homeostasis. Ultimately, it has not been elucidated as to
whether alpha synuclein abnormalities of any kind are the etiological cause of MSA or
simply an observed symptom of this disease.
The first known clinical occurrence of MSA was published in 1900 (1). It was
reported that two individuals suffered from adult-onset sporadic ataxia with
extrapyramidal, urinary and hypotensive symptoms. Autopsy on one of these individuals
revealed gross degeneration of the olives, pons and cerebellum. It is in this report where
the term olivopontocerebellar atrophy was first used. Twenty-five years later, Bradbury
1

and Eggleston reported a similar occurrence in three patients with idiopathic postural
hypotension (2) and in 1960, Shy and Drager described a case study of an individual with
severe parkinsonism, multiple autonomic systems failure, atrophy and postural
hypotension (3). Gross degeneration of the inferior olives, caudate nucleus and the
intermediolateral columns of the spinal cord was observed upon autopsy. One year later,
autopsy of three individuals with pontine, olivary, cerebellar and striatonigral
degeneration was reported. Shy and Drager would define these combinatorial symptoms
as “Shy-Drager Syndrome”.
Less than a decade later, Graham and Oppenheimer coined the term “Multiple
System Atrophy” (4). Prior to this, MSA had been categorized as numerous distinct
diseases, however, Graham and Oppenheimer recognized a key feature that MSA
subtypes had in common. Specifically, they noted that neuronal atrophy was present in
all MSA cases, leading them to posit that MSA symptoms result from combinatorial
dysfunction of different brain regions that stemmed from neuronal atrophy. This
observation would come to be a defining feature of MSA.
Pathology
Several subtypes of MSA are used to define key characteristics of this multifactorial
disease (5). MSA-P is used to characterize MSA with Parkinson’s-like symptoms and
predominantly includes extrapyramidal features with striatonigral degeneration. MSA-C
is used to characterize MSA with predominant cerebellar dysfunction with progressive
ataxia. Shy-Drager Syndrome is still used today, albeit less frequently, and is
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characterized by features of Parkinsonism with pronounced autonomic nervous system
failure. MSA subtypes attempt to categorize the numerous pathological symptoms that
can occur in MSA.
Those with MSA-P predominantly experience striatonigral degeneration (SND) of
dopaminergic neurons in the substantia nigra pars compacta, GABAergic neurons of the
caudate-putamen and medium-spiny neurons. Those with MSA-C predominantly
experience olivopontocerebellar atrophy (OPCA) which includes degeneration of Purkinje
neurons in the cerebellar cortex as well as neurons of the pontine nuclei and inferior
olivary complex. Those with either MSA-P and MSA-C subtypes also experience
degeneration of the brainstem and spinal cord as well as numerous other regions in the
brain.
Approximately 60-82% of MSA patients have developed akinetic-rigid
parkinsonism at the time of diagnosis and these individuals respond poorly to L-Dopa
treatment. Approximately 10-30% of MSA patients have cerebellar features at the time of
diagnosis (6). MSA-P is the most common form of MSA; 87-98% of those with MSA will
develop some feature of parkinsonism (7). Multiple features of parkinsonism, which occur
in 33-64% of patients, include irregular, jerky postural tremors and rest tremors.
Approximately 8% of MSA patients experience pill-rolling tremors that are typically
indicative of PD. One fifth of MSA patients report an increased rate of falling during their
first year of disease progression, however, falling is typically indicative of Progressive
Supranuclear Palsy (PSP), which is the rarest synucleinopathy known to date. Cerebellar
features predominantly include gait ataxia in 90% of patients, limb ataxia in 87% of
3

patients and nystagmus in 38% of patients. Additionally, 47% of patients will develop
kinetic ataxia, 69% will develop scanning dysarthria, 23% will develop cerebellar
oculomotor dysfunction and 24% will develop intention tremors.
The first reported MSA symptom for most patients is speech impairment. Those
with MSA-C present with scanning dysarthria while those with MSA-P tend to have highpitched, quivery and croaky intonations while speaking. Ultimately, most of those with
MSA lose their ability to speak. Dysphagia is a prevalent MSA symptom and there are
numerous incidences of MSA patients choking to death.
Erectile dysfunction is thought to be the first MSA symptom for men (8), and both
men and women experience sexual deficits. 73% of both men and women have urinary
dysfunction with urge incontinence and 48% lack the ability to completely empty the
bladder during urination (9). One third of patients will experience both urge
incontinence and urinary retention. Micturition is also an early MSA symptom and is
generally considered more severe than in those with PD.
Orthostatic hypotension (OH) occurs in about 50% of MSA cases. Clinically, MSA
diagnostic criterion is met when a minimum of 30 mmHG drop in blood pressure and a 15
mmHG drop in diastolic blood pressure occurs. Syncope after a sudden postural change is
quite common in MSA and is a known symptom that dates back to Shy and Drager’s
initial clinical report from 1960. Other cardiovascular autonomic failures occur and often
include dizziness, nausea, palpitations, tremulousness, headaches and an overall general
weakness (10).
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Respiratory dysfunction is predominantly marked by inspiratory stridor in 9-69%
of MSA cases and is thought to occur primarily from the pathological adduction of the
vocal cords. Degeneration of the nucleus ambiguus culminates in the paralysis of the
vocal cord abductor muscles (11) and deep, involuntary gasps or sighs occurs in 43% of
patients. Several sleeping disorders are associated with the observed respiratory
dysfunction in MSA patients. Sleep apnea is reported in 40% of patients (12) and likely
results from degeneration of the pontomedullary respiratory centers. Prolonged cardiac
ventricular arrhythmias and hypoxemia from sleep apnea and laryngeal patency can
result is nocturnal sudden death (13). Nocturnal sudden death ultimately claims the lives
of most individuals who have fully progressed MSA.
Most individuals with MSA have gastrointestinal dysfunction. This includes
chronic constipation, upper and lower gastrointestinal dysfunction, anhidrosis and
hypohidrosis. Those with MSA-C will typically have pyramidal features with hyperreflexia
and Babinski signs.
By the third year of disease progression, 68% of patients will have severe postural
instability. Recurrent falling episodes can happen to MSA patients while they are still able
to walk, though this is less common in MSA and is typically indicative of PSP. Abnormal
posture occurs in all MSA cases; camptocormia is more pronounced when an individual is
walking and decreases while sitting (14). One hallmark of MSA is the eventual inability to
unbend their neck or back without aid; individuals with progressed MSA tend to
spontaneously lean forward and will remain in that posture until they are physically
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moved back into their normal resting posture. Additionally, Pisa Syndrome and
disproportionate antecollis are symptoms of MSA.
Epidemiology
Few epidemiological studies have been conducted to date and such efforts have
been hampered by MSA’s rarity of occurrence. Despite this, some data have been
collected. One 14-year cohort study in Minnesota estimates incidence rates to be at 0.6
per 100,000 people. This rate increased to 3 per 100,000 people in those who are aged fifty
and over (15). A study conducted in Iceland produced data with comparable rates to that
obtained from the Minnesota study (16). Incidence rates obtained from Russian and
Swedish populations differed slightly when compared to the other two studies (17, 18),
though not appreciably. The World Health Organization has estimated European
populations to have prevalence rates of 3.4 per 100,000 people which rises to 7.8 per
100,000 for individuals over 40 years of age (16). The highest estimated prevalence rate is
4.9 per 100,000 people (19).
Alpha Synuclein
The hallmark of the synucleinopathies is the aggregation, fibrillization and
subsequent accumulation of alpha synuclein in specific cell types and regions of the
central nervous system. Accumulation of alpha synuclein is so severe that it is used in
postmortem histological analysis of brain tissues where the locations of alpha synuclein
aggregates are used to confirm which type of synucleinopathy the patient had. In MSA,
alpha synuclein aggregation occurs primarily in the cytoplasm of oligodendrocytes and is
6

termed Glial Cytoplasmic Inclusions (GCI’s). Glial Nuclear Inclusions (GNI’s), Neuronal
Cytoplasmic Inclusions (NCI’s) and Neuronal Nuclear Inclusions (NNI’s) can also be
found, albeit less predominantly. As such, alpha synuclein aggregation and deposition
occurs in neurons and glial cells. It is well characterized, however, that cell death of
oligodendrocytes occurs first, followed by neuronal cell death (20).
Alpha Synuclein is a small intrinsically disordered protein consisting of 140 amino
acids. Coded by the gene, SNCA, alpha synuclein is a prevalent neuronal protein,
accounting for approximately 1% of total cytosolic proteins in neurons (21). Alpha
synuclein is mainly localized to presynaptic termini, however, as will be discussed later, it
can also be found localized to mitochondria and within the nucleus of neurons.
Alpha synuclein is expressed in a wide variety of tissues and is more abundantly
expressed in neurons and platelets when compared to any other cell type (22). Data on
alpha synuclein expression in oligodendrocytes has provided mixed results. Until
recently, most studies concluded that alpha synuclein was not expressed in
oligodendrocytes (23). More recent studies utilizing techniques such as laser-capture
microdissection have established that oligodendrocytes do express alpha synuclein and
moreover, that alpha synuclein expression is higher in oligodendrocytes in MSA brain
when compared to control brains (24). Other studies, for example, have established that
oligodendrocyte lineage cells express alpha synuclein and expression significantly
decreases during oligodendrocyte maturation (25). Given this information,
oligodendrocytes do express alpha synuclein but this is minimal when compared to
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neuronal expression and as such, the source of pathogenic alpha synuclein is likely
predominantly derived from neurons.
The N terminal half of alpha synuclein is well characterized and is composed of
two amphipathic alpha helices that are separated by a small hinge region. The C terminal
half of alpha synuclein is poorly characterized and studies on this region are greatly
hampered given that it is intrinsically disordered. X-Ray Crystallographic structural
analysis has not been successful to date given the inability of wild type alpha synuclein to
form crystals. A single structure has been obtained by NMR structural analysis and
importantly, this structure was only able to be obtained by stabilizing human wild type
alpha synuclein onto synthetic micelles (26). Cryogenic Electron Microscopy studies have
also yielded a stable structure of fibrillated human wild type alpha synuclein (27).
Numerous small nucleotide polymorphisms (SNP’s), duplications and triplications
have been identified in SNCA, however, none of these SNP’s have been correlated to MSA
pathology (28). For example, the A53T, A30P, E46K, and H50Q mutations are associated
with familial PD and the A18T and A29S mutations are associated with sporadic PD (29).
These mutations have been shown to abrogate membrane binding due to nonconservative amino acid substitutions in the amphipathic helical domains. Additionally,
duplications and triplications of SNCA, though rare, have also been associated with early
onset PD. This information demonstrates that perturbing alpha synuclein's membrane
binding function can give rise to PD and its associated symptoms. Overexpression of
alpha synuclein through upregulation of SNCA, aside from duplications or triplications,
can also give rise to PD. Knockout of alpha synuclein in mouse embryos results in loss of
8

dopaminergic neurons of the substantia nigra (30) and silencing of SNCA results in nigral
degeneration on par with alpha synuclein overexpression (31). Though SNCA is not
mutated or overexpressed in MSA, studies on alpha synuclein in PD allow one to
elucidate alpha synucleins normal function which is necessary towards understanding its
potential relevance and contribution towards MSA pathogenesis.
Despite decades worth of research, the function of alpha synuclein has yet to be
elucidated, however, the identification of alpha synuclein’s membrane binding motifs led
to a slew of functional studies that began to shed light on alpha synuclein’s function (3234). Alpha synuclein lays down into phospholipid bilayers in a parallel manner (35).
Numerous studies have demonstrated that alpha synuclein can influence the curvature of
membranes upon membrane binding and this is due in part to the flexibility of the
amphipathic helices imparted by the hinge region that separates the two alpha helical
motifs (36). Importantly, the hydrophilic C terminus of alpha synuclein weakly and
transiently binds to lipid membranes (37) demonstrating that the C terminus does not
significantly contribute towards membrane binding, which likely holds a different
function altogether.
Alpha synuclein has a predisposition towards binding to anionic phospholipids
including phophatidylserine and phospatidylglycerol (38, 39). Furthermore, alpha
synuclein has a preference for binding to lipid rafts (40) and some of the SNCA
mutations, namely A30P, contributes to decreased membrane binding efficiency (41).
Numerous conformations of membrane-bound alpha synuclein have been proposed that
not only allow for influencing curvature of membranes but these conformations can also
9

impact the formation of vesicles and the resulting size of the vesicles. Alpha synuclein can
form single elongated alpha-helix, broken alpha-helix and elongated helix conformations
(42). Importantly, alpha synuclein has predisposition for binding to membranes with
pronounced curvature and then secondarily influences further changes to membrane
curvature. As such, alpha synuclein may preferentially bind to vesicles including
exosomes, endosomes and synaptic vesicles.
Alpha synuclein's normal function in neurons is predominantly thought to revolve
around neurotransmitter release and recycling (43-45). Numerous studies implicate alpha
synuclein as having a central role in maintenance and regulation of synaptic vesicles and
the synaptic vesicle pool, overall. Natively, unfolded alpha synuclein exists in monomeric
forms at the synapse. Alpha synuclein then adapts to the alpha helical structure upon
membrane binding and may form helical multimers upon binding to synaptic vesicles.
This binding event stabilizes the target membrane and protects alpha synuclein from
aggregation and potentially oxidative stress as well (46).
Mitochondria
Mitochondrial health and homeostasis are essential towards normal cellular
health, and deficits in mitochondrial function have taken a central role in the pathology
of numerous neurological diseases, including PD and MSA (47, 48). Mitochondria are
dynamic organelles; in neurons, mitochondria show dynamic localization throughout
complex neuronal architecture (49, 50). Kinesins and dynein, in part, facilitate movement
of mitochondria up and down axons (51) and actin-facilitated movement has been
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observed as well (52). Mitochondrial morphology is altered depending on where
mitochondria are located. Mitochondrion width tends to remain fixed at 1 µm whereas
mitochondrial length can vary greatly; in axons, mitochondria are typically between 1-3
µm in length and mitochondria in dendrites tend to be longer (53). Given the high energy
requirements of neurons, especially at the synapse, mitochondrial localization
throughout the neuron is essential, albeit, poorly understood.
Each mitochondrion contains 2-10 genomes and the number of mitochondrion per
cell depends on the overall energy requirements of the cell (54). For example, it is
estimated that 1000-2000 mitochondria are in each liver cell, composing one fifth of the
entire cell mass. Considering that the brain uses ~20% of all oxygen when the brain itself
is only 2% of the overall body mass (55), it is likely that mitochondrial numbers are
equally as high, if not higher, in neurons as they are in liver cells.
The Warburg Effect was postulated in 1924 and describes the observation that
immortalized in vitro cells predominantly use glycolysis over aerobic respiration (56). The
inverse Warburg Effect was postulated several decades later and expanded on the
Warburg Effect; healthy neurons predominantly utilize oxidative phosphorylation
whereas healthy glia predominantly utilize glycolysis. Important to the inverse Warburg
Effect is the observation that Kreb’s cycle derived lactate, produced by glia, is secreted as
part of the complex neurotropic support glia provide to neurons (57, 58). As such, lactate
secretion by glia is currently thought to supplement neuronal energy production.
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It is well established that mitochondrial genomes become heteroplasmic with
increasing age (59, 60). Kang et al found that iPSCs derived from numerous tissue sources
contain low levels of heteroplasmic point mutations and the frequency of these mutations
increase with age (61). Importantly, many of these mutations occurred in RNA coding
genes that can lead to defects in respiratory functions, especially with consideration that
the mitochondrial genome encodes for protein subunits found in complex’s I, III, IV and
V. The occurrence of mitochondrial DNA heteroplasmy in neurological diseases has been
under investigation for decades (62-64). Numerous labs have directly implicated
mitochondrial DNA mutations, including substitutions and deletions, and subsequent
heterogeneity of the mitochondrial pool to be directly correlated to a slew of neurological
diseases (65, 66).
Mitochondrial DNA mutations have been described in MSA. One study was
conducted on a family with known familial MSA of the cerebellar subtype. Sequencing of
mitochondria isolated from blood and a muscle biopsy from this patient provided data
that an exceptionally large mitochondrial DNA deletion of 12,806 bp was present in the
mitochondria from the muscle biopsy, but not the mitochondria isolated from blood cells
(67). This mutation spanned all genes encoding oxidative phosphorylation related
proteins. Morphologically, the mitochondria from the muscle biopsy were enlarged and
included mitochondria with abnormal shapes, including elongated and branched
mitochondrion.
Genomic DNA mutations have also been described in MSA. The best studied
genomic mutation is in the gene, COQ2, and as such further implicates mitochondrial
12

deficits as a potential cause of MSA (68). COQ2 is a gene that codes for the enzyme
parahydroxybenzoate-polyprenyltransferase which catalyzes one of the final reactions in
the biosynthesis of ubiquinone (CoQ). Ubiquinone is essential in the electron chain
transport, and mutations to COQ2 result in loss of function and ultimately, deficits in
ubiquinone synthesis. Importantly, COQ2 mutations have only been linked to familial
inheritance of MSA in those with Asian ancestry.
Alpha Synuclein and Mitochondria
It has been well established that alpha synuclein has a high propensity towards
binding mitochondrial membranes as it contains a mitochondrial localization signal in
the N-terminal domain. Nakamura et al demonstrated that overexpression of alpha
synuclein was sufficient to drive mitochondrial fission and that the rate of fission
exceeded the rate of fusion (69). Morphological changes to other organelles did not occur
nor was the mitochondrial membrane potential perturbed, however, following
mitochondrial fragmentation, a decrease in respiration was observed which culminated in
neuronal death. Other labs report similar findings; overexpression of alpha synuclein in in
vivo and in vitro neurons results in mitochondrial fragmentation (70).
Alpha synuclein has been reported to directly bind to mitochondrial proteins in
addition to binding to mitochondrial membranes. Di Maio et al reported that alpha
synuclein bound to TOM20 when in vitro dopaminergic neurons were treated with
rotenone. Binding of TOM20 to its coreceptor, TOM22, was impaired as a result (71). This
result was recapitulated in rats injected with AAV2-SNCA constructs and in postmortem
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PD brain tissues. The authors also found that import of proteins into mitochondria was
drastically reduced which holds significance considering some 1500 nuclearly encoded
proteins are present within mitochondria. Complex I activity was assessed and was found
to be diminished as well, presumably as a result of loss of protein import.
Given that the hallmark of the synucleinopathies is the accumulation of
aggregated and fibrillated alpha synuclein, Ludtmann et al identified normal and
pathological differences when in vitro neurons/astrocytes in a coculture system were
treated with either alpha synuclein monomers or oligomers. The authors found that
monomeric alpha synuclein improved ATP synthase efficiency whereas alpha synuclein
oligomers localized to the vicinity of ATP synthase but impaired complex I-dependent
respiration (72). They also found that ATP synthase beta units were oxidized and that
mitochondrial lipids were peroxidated. Ultimately, the mitochondrial permeability
transition pore (mPTP) was aberrantly opened causing mitochondrial swelling and
eventually cell death.
Wang et al performed similar experiments using primary mouse or rat cortical
neurons. Alpha synuclein amyloid fibrils were preformed and then treated to either
source of cortical neurons. Using serine 129 phosphorylated alpha synuclein as a
measurement of the exogenously added pathogenic alpha synuclein, the authors found
that aggregated alpha synuclein bound to mitochondria with a higher propensity than
endogenous monomeric alpha synuclein (73). These findings were confirmed in animal
models and in postmortem PD and MSA brains. The rate of oxygen consumption was
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measured in in vitro experiments and cells incubated with aggregated alpha synuclein had
significantly lower rates of respiration.
Mitophagy
In recent years, interest in mitophagy has taken center stage in the pathogenesis of
numerous synucleinopathies, including PD and MSA. Typically considered a form of
selective macroautophagy that specifically removes damaged or superfluous
mitochondria, recent interest in mitophagy revolves around the possibility of aberrant
activation of mitophagy machinery or conversely, defects in mitophagy processes.
Mitochondrial metabolism is intimately coupled with the generation of Reactive
Oxygen Species (ROS) that inherently damage components of the mitochondrion,
including lipids, proteins and nucleic acid. Cellular homeostasis demands that damaged
components of mitochondria be repaired or if damage is excessive, that the
mitochondrion be degraded in its entirety. Lack of repair or degradation of damaged
mitochondria may lead to further generation of ROS and the potential for proapoptotic
proteins to be released into the cytosol, ultimately resulting in cellular death (74).
Mitophagy can be classified into three distinct variants (75). Type I mitophagy
occurs primarily during nutrient deprivation. Mitochondria and mitochondrial fission
products are engulfed by preautophagic structures (PAS) forming mitophagosomes.
Following mitochondrial sequestration, the mitophagosome acidifies leading to
mitochondrial depolarization and subsequently, hydrolytic digestion by lysosome derived
proteolytic proteins. Type II mitophagy occurs primarily with physical damage to
15

mitochondria. For example, adequate photodamage to mitochondria may result in
mitochondrial depolarization and the recruitment of LC3 to the mitochondrial outer
membrane. LC3 then recruits the mitophagosome leading to acidification and hydrolytic
digestion by lysosome derived proteolytic proteins. Type III mitophagy is technically a
form of micromitophagy and is marked by the formation of mitochondria derived vesicles
(MDV’s) from mitochondria and at the expense of the mitochondria. MDV’s are often
enriched in oxidized mitochondrial proteins and often localize to multivesicular bodies.
MDV’s contained within multivesicular bodies are then either degraded by the
autolysosome or are released into the extracellular environment.
Mitophagy type II and type III are currently viewed as being the most pertinent to
the synucleinopathies. Under normal physiological conditions, PINK1 continuously
localizes to mitochondria where it is rapidly degraded by matrix processing peptidases.
PINK1 is then further degraded in the cytosol by the proteasome (76). Damaged
mitochondria or depolarized mitochondria leads to a reduction of PINK1 cleavage and
PINK1 subsequently accumulates on the mitochondrial outer membrane through
interaction with TOM. PINK1 then autophosphorylates itself where it then ubiquitinates
its own serine 65 residue. Ubiquitination of serine 65 recruits Parkin to the mitochondrial
outer membrane where it is then activated by phosphorylation. Parkin then
polyubiquitinates numerous mitochondrial substrates (77) including VDAC1, MFN 1/2
and Miro 1 which induces mitochondrial fission and mitophagy (78) through eventual
recruitment of LC3 adapters. PINK1 and Parkin are two genes that are mutated in
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Parkinson’s Disease, therefore, deficits in mitophagy are central to the pathology of some
variants of PD.
LC3 may also act on mitochondria in a ubiquitin-independent manner through
binding to LC3 receptors. One such receptor is Bnip3 (BCL2/Adenovirus E1B 19 kDa
Interacting Protein 3). Bnip3 homodimerizes on the mitochondrial outer membrane and
is activated by phosphorylation at Ser17 and Ser24. Bnip3 suppresses cleavage of PINK1
(79) thereby activating mitophagy mechanisms as previously discussed.
Bnip3 contains an atypical BCL-2 homology domain 3-only (BH3-only) motif that
typically allows for binding to antiapoptotic BCL-2 family members. Bnip3 is unique,
however, since it interacts with Bcl-2 and other family members through its
transmembrane domain instead of the BH3-only domain (80). Early studies identified
Bnip3 to be an apoptosis-inducing protein that became functionally active after
overcoming Bcl2 suppression. In this regard, Bnip3 interacts with Bax and Bak to induce
apoptosis (81). Bnip3 also contains a LC3-Interacting Region (LIR) domain allowing for
direct binding to LC3 proteins and it also contains a transmembrane domain for
integration into the mitochondrial outer membrane (82). Under the control of Hypoxia
Inducible Factor 1 (HIF1), Bnip3 was primarily thought to induce cell death through
apoptosis and necrosis during hypoxic conditions. For example, it has been reported that
Bnip3 can induce autophagy mediated cell death in gliomas in response to hypoxia,
ceramide or arsenic trioxide treatment (83). Conversely, it has also been reported that
Bnip3 can contribute to cell survival. Bnip3 was found to be upregulated in solid tumors
and specifically in cells that were still viable yet were in a hypoxic region of the tumor
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(84). It is hypothesized that mitophagy mechanisms occur during hypoxia so as to
prolong cell survival at the expense of a portion of the mitochondrial pool.
Bnip3 is significantly upregulated in numerous tumor cells whereas it is minimally
expressed in normal cells due it its ability to cause cell death. In tumors where
upregulation occurs, tumors tend to be more aggressive. Interestingly, it has also been
found that Bnip3 expression is silenced by methylation in some tumor cells that are
undergoing an epithelial to mesenchymal transition (85).
In 2007, Dr. Ide’s lab published a paper on gene expression changes from the
rostral pons of Multiple System Atrophy patients (86). Out of tens of thousands of genes
that were assessed for differential expression, 254 genes were found to be differentially
regulated; 180 genes were downregulated and 74 genes were upregulated. Genes that were
downregulated included genes involved with mitochondrial function, ubiquitinproteasome function, protein modification, glycolysis/metabolism and ion transport.
Genes that were upregulated included genes involved with transcription/RNA
modification, inflammation, immune system function and oligodendrocyte maintenance
and function.
The aim of this master’s thesis is to build upon the information provided in the Ide
laboratory’s 2007 publication. Specifically, prior students have developed a MSA cell
culture model using the C6 rat glioma cell line. Using this cell line, exogenously added
human wild type alpha synuclein is added to culture media and then incubated for
variable amounts of time. Prior students have focused on establishing that alpha

18

synuclein is endocytosed and that mitochondrial membrane potentials are perturbed in
an alpha synuclein dose dependent manner. The aim of my study is to utilize various PCR
methodologies to identify genes that respond to alpha synuclein treatment with the
primary objective of focusing on gene candidates that were found to be differentially
regulated from the Ide laboratory’s 2007 publication.
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CHAPTER 2
PCR ANALYSIS ON THE EFFECTS OF ALPHA SYNUCLEIN TREATMENT ON C6 RAT
GLIOMA CELLS
Exploratory PCR Array and Bnip3/Hprt1 ddPCR
Considering alpha synucleins probable role in MSA pathogenesis, an exploratory
PCR array was purchased to assess if alpha synuclein treatment could result in the
differential regulation of any oxidative stress related genes. Genes on the rat oxidative
stress PCR array create proteins that are involved with mitochondrial health, homeostasis
and function. Furthermore, several genes on the rat oxidative stress PCR array were
identified by the Ide laboratory as being differentially regulated in those with MSA. The
C6 cell culture model that the Ide laboratory developed was utilized so as to identify
differentially regulated genes in glial cells when they were treated with a single dose of
alpha synuclein. Identification of any gene that was differentially regulated after a single
treatment with alpha synuclein may hold significance in MSA pathogenesis.
ddPCR was then used to fully assess the effects of alpha synuclein treatment at
multiple time points following identification of the Bnip3 candidate gene. ddPCR was
chosen as it is the most sensitive PCR technique described to date and the particular
strength of ddPCR is the absolute quantification of mRNA transcripts without the use of
an external calibration curve or housekeeping gene. Additionally, the sensitivity and
accuracy of ddPCR is particularly important considering that cell culture experiments
were not replicated in this pilot study.
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Materials and Methods
Cell Culture
C6 rat glioma cells were procured from the ATCC (ACTT© CCL-107™) and cultured in F12K medium containing 15% horse serum and 2.5% fetal bovine serum. Cells were
maintained in T25 flasks and utilized for experiments prior to cells reaching confluency.
Briefly, cells were washed once with 1x HBBS and then trypsinized at 37°C until cells were
detached from the cell culture flask. Trypsin was then quenched with complete medium
and cell counts were obtained using a hemocytometer. Cells were then plated at a density
of 4x104 cells/mL per 24-well culture plate with each well containing 1 mL media. Three
days after plating, cells that were approximately 90% confluent were treated with 1 mL of
32 µg/mL alpha synuclein (rPeptide, Cat# S-1001-1) in complete medium for 1 hour, 2
hours or 4 hours in duplicate. Each time point included duplicate control wells that
received complete medium and the identical volume of water used for alpha synuclein
dosing.
At a later date, cells were plated as described above, however, cells were treated with 1 mL
of 32 µg/mL alpha synuclein (rPeptide, Cat# S-1001-1) in complete medium for 12 hours, 24
hours or 48 hours in duplicate one day after plating. All wells were harvested prior to cells
reaching confluency. Each time point included duplicate control wells that received
complete medium and the identical volume of water used for alpha synuclein dosing.
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RNA Extraction and Purification
Cells were harvested for RNA at the time points above using QIAgen’s RNeasy Fibrous
Tissue Mini Kit (Cat# 74704) per the manufacturer’s specifications and with minor
modifications. Briefly, cells were washed once with 1X HBBS and then 320 µL Buffer RLT
supplemented with βME (10 µL βME per 1 mL Buffer RLT) was pipetted into each well on
ice. Following a short incubation on ice, lysates were collected and stored frozen at -20°C.
On the day of purification, cell lysates (300 µL) were thawed at RT and then 590 µL
nuclease-free water and 10 µL Proteinase K were pipetted to each lysate and mixed by
pipetting. Lysates were then incubated at 55°C for 10 minutes in a VorTemp™ 56 with 1000
rpm shaking. Following this, 450 µL 100% EtOH was pipetted to each lysate and then
incubated for 5 minutes at RT after mixing by pipetting. Lysates were then pipetted to
individual columns and centrifuged at 13,000 rpm for 1 minute. The columns were then
washed with 350 µL Buffer RW1 and centrifuged as described above. Columns were then
treated with DNase I for 15 minutes per the manufacturers specifications and then
columns were washed again with 350 µL Buffer RW1 and twice with 500 µL complete
Buffer RPE. Following a 1 minute centrifugation to remove residual wash buffer, RNA was
then eluted in 40 µL nuclease-free water. Purified RNA was then aliquoted and stored at 80°C.
RNA Quantification and cDNA Synthesis
RNA was quantified using the NanoDrop 8000. The means of duplicate measurements
were used for downstream applications. cDNA was synthesized using the High-Capacity
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cDNA Reverse Transcription Kit with RNase Inhibitor (Applied Biosystems, Cat#
4374967) per the manufacturer’s specifications. Briefly, 1000 ng of each RNA sample was
pipetted into a 20 µL total reaction and then the reverse transcription reaction was
performed at 25°C for 10 minutes, 37°C for 120 minutes and then 85°C for 5 minutes with
an infinite hold at 4°C on a GeneAmp 9700. Following completion of the reverse
transcription reaction, 80 µL of nuclease-free water was pipetted to each reaction. cDNA
was then aliquoted and stored at -80°C.
2100 BioAnalyzer
RNA integrity was assessed by following the manufacturer’s specifications.
RT-qPCR
The Rat Oxidative Stress PCR Array (ROSL-I) was purchased from Real Time Primers,
LLC and used per the manufacturer’s specifications with some modifications. Briefly, the
master plate was thawed at RT and then centrifuged for 5 minutes at 1500 rpm to drop the
liquid down to the bottom of the plate. Final PCR array conditions per well were 0.1 µM
forward and reverse primer, 1x Power SYBR™ Green PCR Master Mix (Applied Biosystems,
Cat#4367659) and 10 ng cDNA in a final reaction volume of 20 µL. Once plated, the PCR
plate was centrifuged for 5 minutes at 1500 rpm to drop liquid down to the bottom of the
plate. The following cycling conditions were used: 50°C for 2 minutes, 95°C for 10 minutes
and 50 cycles of 95°C for 10 seconds and 58°C for 45 seconds. The PCR array was
performed on an Applied Biosystems 7900HT Fast Real-Time PCR System using the 9600
Emulation mode. Data was manually analyzed using delta delta Ct methodology.
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ddPCR
Each ddPCR reaction consisted of 0.1 µM forward and reverse primer from the Rat
Oxidative Stress PCR Array (ROSL-I), 1x QX200™ ddPCR™ EvaGreen Supermix (BioRad,
Cat#186-4034) and 2 ng cDNA in a final reaction volume of 20 µL. Briefly, the complete
ddPCR reaction was pipetted into the QX200 Automated Droplet Generator to generate
droplets. The PCR plate was then placed into the C1000 Touch Thermal Cycler with 96Deep well Reaction Module and cycled as follows: 95°C for 5 minutes and 40 cycles of
95°C for 30 seconds and 58°C for 60 seconds. The reaction products were then cooled to
4°C for 5 minutes, raised to 90°C for 5 minutes and then lowered to 4°C with an infinite
hold. Ramp rates of 2°C/second were used. Reaction products were then read on the
QX200 Droplet Reader. Bnip3 and Hprt1 primer sets were used. Each sample was assayed
in duplicate.
Results
Exploratory PCR Array
The specific aim of the exploratory PCR Array was to identify any differentially
regulated genes when C6 rat glioma cells were treated with a single dose of 32 µg/mL
alpha synuclein. Previous students in Dr. Ide’s laboratory had developed the C6 rat
glioma cell model to mimic MSA pathology, therefore, the secondary aim of the
exploratory PCR Array was to recapitulate any differential gene expression observed in
MSA patients. C6 rat glioma cells were treated with 32 µg/mL alpha synuclein, in
duplicate cell culture wells, for 1 hour, 2 hours or 4 hours. Purified RNA was of similar
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concentration and high purity (Figure 1) and RNA was highly intact as assessed by the
BioAnalyzer (Figure 2). One treated sample and one control sample from the 4 hour time
point was used for the PCR Arrays to identify any potential gene candidates.
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Sample ID
1 hr Control_1
1 hr Control_2
2 hr Control_1
2 hr Control_2
4 hr Control_1
4 hr Control_2
12 hr Control_1
12 hr Control_2
24 hr Control_1
24 hr Control_2
48 hr Control_1
48 hr Control_2
1 hr 32 µg Alpha Synuclein_1
1 hr 32 µg Alpha Synuclein_2
2 hr 32 µg Alpha Synuclein_1
2 hr 32 µg Alpha Synuclein_2
4 hr 32 µg Alpha Synuclein_1
4 hr 32 µg Alpha Synuclein_2
12 hr 32 µg Alpha Synuclein_1
12 hr 32 µg Alpha Synuclein_2
24 hr 32 µg Alpha Synuclein_1
24 hr 32 µg Alpha Synuclein_2
48 hr 32 µg Alpha Synuclein_1
48 hr 32 µg Alpha Synuclein_2

Conc.
(ng/µL)
196.4
195.6
186.7
192.8
181.4
184.7
182.3
190.1
184.8
192.5
166.6
174.1
12.08
11.99
16.38
16.44
42.24
45.82
39.21
41.4
127.8
130.5
179.5
177.9
122
127.9
121.7
128.6
154.9
158
189
203.5
219.7
239.2
163.9
167.7
21.47
21.4
22.08
23.12
36.87
39.67
45.93
47.83
144
152.4
113.3
119.5

260/280

Mean Conc.
(ng/µL)
2.10
196.0
2.11
2.12
189.8
2.12
2.06
183.1
2.07
2.06
186.2
2.05
2.10
188.7
2.12
2.07
170.4
2.08
1.40
12.04
1.48
1.23
16.41
1.19
1.72
44.03
1.67
1.81
40.31
1.82
1.14
129.2
1.10
2.07
178.7
2.07
2.09
125.0
2.09
2.11
125.2
2.12
2.09
156.5
2.09
2.10
196.3
2.06
2.14
229.5
2.11
2.12
165.8
2.09
1.62
21.44
1.68
1.54
22.60
1.53
1.77
38.27
1.79
1.79
46.88
1.72
2.01
148.2
2.01
2.00
116.4
1.99

260/230

2.05
2.04
2.03
2.04
2.03
2.03
2.04
2.04
2.03
2.02
2.04
2.03
2.12
2.04
1.91
1.98
1.98
1.94
2.07
2.01
2.1
2.05
2.1
2.08
2.06
2.04
2.04
2.02
2.03
2.06
2.05
2.04
2.05
2.05
2.04
2.03
1.94
1.93
2.01
1.94
2.02
2.02
2.05
2.04
2.05
2.04
2.06
2.04

%CV
0.29
2.27
1.27
2.96
2.89
3.11
0.53
0.26
5.75
3.84
1.48
0.63
3.34
3.90
1.40
5.22
6.01
1.62
0.23
3.25
5.17
2.87
4.01
3.77

Figure 1. Nanodrop™ 8000 RNA Concentration and Purity Data. Nanodrop™ 8000 data
shows that RNA is highly pure and free of PCR inhibitors.
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Figure 2. Bioanalyzer Data Showing Highly Intact Total RNA. Samples from left to right
are: Ladder (L), 1 hr Control_1 (1), 1 hr Control_2 (2), 2 hr Control_1 (3), 2 hr Control_2 (4),
4 hr Control_1 (5), 4 hr Control_2 (6), 1 hr 32 µg/mL Alpha Synuclein_1 (7), 1 hr 32 µg/mL
Alpha Synuclein_2 (8), 2 hr 32 µg/mL Alpha Synuclein_1 (9), 2 hr 32 µg/mL Alpha
Synuclein_2 (10), 4 hr 32 µg/mL Alpha Synuclein_1 (11) and 4 hr 32 µg/mL Alpha
Synuclein_2 (12).
Data was analyzed by delta delta Ct methodology. Ct values of less than 25 that
resulted in fold changes of 2.0 and greater were considered promising gene candidates
that would be analyzed further using mRNA from the full time course. 88 genes that are
involved in oxidative stress related pathways were analyzed and a single gene, Bnip3 met
the above criteria for additional testing. Bnip3 was downregulated by a fold change of 2.01.
Bnip3 was also identified as being downregulated in MSA patients.
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Bnip3 and Hprt1 ddPCR; Short Time Course
Having potentially identified a gene that responds to alpha synuclein treatment, it
was decided to run the short time course experiment using Bnip3 and Hprt1 primer sets to
assess the early effects of alpha synuclein treatment on these genes. The Hprt1
housekeeping gene was not necessary to run considering that ddPCR allows for absolute
quantification without an external calibration curve or housekeeping gene for
normalization, however, it was included as a control to account for technical
implementation of the ddPCR. Hprt1 was also the most stably expressed housekeeping
gene from the PCR Array pilot experiment, having provided identical Ct values to the
hundredth of a decimal.
The short time course was conducted on cells that were approximately 90%
confluent at the time of dosing and this experimental methodology was implemented so
as to provide the highest total RNA yield as possible. This was also the source of total
RNA used in the PCR Array pilot experiment. Importantly, C6 cells were dosed when cells
were subconfluent.
For Bnip3 gene expression by ddPCR absolute quantification, the 1 hour, 2 hour
and 4 hour time points had a 14.74% increase, 9.45% decrease and a 10.35% decrease,
respectively (Figure 3) when treated with alpha synuclein. Mean copy numbers for the 1
hour, 2 hour and 4 hour control samples are 6445, 6140 and 5650, respectively. Mean copy
numbers for the 1 hour, 2 hour and 4 hour alpha synuclein treated samples are 7395, 5560
and 5065, respectively.
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For Hprt1 gene expression by ddPCR absolute quantification, the 1 hour, 2 hour
and 4 hour time points had a 10.60% increase, 4.93% decrease and a 1.57% decrease,
respectively (Figure 4) when treated with alpha synuclein. Mean copy numbers for the 1
hour, 2 hour and 4 hour control samples are 3138, 3340 and 3593, respectively. Mean copy
numbers for the 1 hour, 2 hour and 4 hour alpha synuclein treated samples are 3471, 3175
and 3536, respectively.

Figure 3. Bnip3 mRNA Gene Expression by ddPCR (Short Time Course). C6 Cells were
treated with 32 µg/mL alpha synuclein for 1 hour, 2 hours or 4 hours. RNA was extracted,
purified and analyzed by ddPCR. Data are represented as mean copy numbers from two
cell culture wells that were analyzed in duplicate PCR’s.

29

Figure 4. Hprt1 mRNA Gene Expression by ddPCR (Short Time Course). C6 Cells were
treated with 32 µg/mL alpha synuclein for 1 hour, 2 hours or 4 hours. RNA was extracted,
purified and analyzed by ddPCR. Data are represented as mean copy numbers from two
cell culture wells that were analyzed in duplicate PCR’s.
Bnip3 and Hprt1 ddPCR; Long Time Course
Data from the short time course experiment described in the previous section
suggested that Bnip3 expression decreased when C6 cells were treated with alpha
synuclein over a short amount of time, therefore, a longer time course experiment was
conducted to assess if Bnip3 was more substantially downregulated after up to two days
post treatment with alpha synuclein. The long time course utilized the same experimental
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methodology as described in the previous section, however, the long time course
experiment was conducted on cells that were allowed to grow up to 90% confluency by
the second day after treatment; this methodology was implemented so that cells would
not reach confluency during the course of the experiment. As such, cells were cultured in
the presence of alpha synuclein, as opposed to the short time course experiment where
subconfluent cells were dosed and harvested no more than four hours after dosing.
For Bnip3 gene expression by ddPCR absolute quantification, the 12 hour, 24 hour
and 48 hour time points had a 3.63% decrease, 16.75% decrease and a 29.26% decrease,
respectively (Figure 5) when treated with alpha synuclein. Mean copy numbers for the 12
hour, 24 hour and 48 hour control samples are 3400, 5015, and 89150, respectively. Mean
copy numbers for the 12 hour, 24 hour and 48 hour alpha synuclein treated samples are
3276, 4175 and 63065, respectively.
For Hprt1 gene expression by ddPCR absolute quantification, the 12 hour, 24 hour
and 48 hour time points had a 7.71% increase, 3.48% decrease and a 3.74% decrease,
respectively (Figure 6) when treated with alpha synuclein. Mean copy numbers for the 12
hour, 24 hour and 48 hour control samples are 3528, 4455 and 33255, respectively. Mean
copy numbers for the 12 hour, 24 hour and 48 hour alpha synuclein treated samples are
3800, 4300 and 32010, respectively.
The exploratory PCR array identified one candidate gene as being differentially
regulated when C6 cells were treated with a single dose of alpha synuclein. ddPCR
analysis confirmed that Bnip3 was consistently downregulated over time. Bnip3’s essential
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role in mitophagy offered a promising lead into how MSA pathogenesis may occur and
reflects some of the current hypotheses researches have pertaining to synucleinopathy
pathogenesis.

Figure 5. Bnip3 mRNA Gene Expression by ddPCR (Long Time Course). C6 Cells were
treated with 32 µg/mL alpha synuclein for 12 hours, 24 hours or 48 hours. RNA was
extracted, purified and analyzed by ddPCR. Data are represented as mean copy numbers
from two cell culture wells that were analyzed in duplicate PCR’s.
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Figure 6. Hprt1 mRNA Gene Expression by ddPCR (Long Time Course). C6 Cells were
treated with 32 µg/mL alpha synuclein for 12 hours, 24 hours or 48 hours. RNA was
extracted, purified and analyzed by ddPCR. Data are represented as mean copy numbers
from two cell culture wells that were analyzed in duplicate PCR’s.
mtDNA and gDNA Analysis by ddPCR and qPCR
The Bnip3 ddPCR results indicated that the Bnip3 gene was downregulated over
time when C6 cells were treated with alpha synuclein. Considering Bnip3’s essential role
in mitophagy, it was hypothesized that alpha synuclein treatment was leading to
clearance of mitochondria from C6 cells. Furthermore, it was hypothesized that Bnip3 was
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downregulated in order to preserve the remaining mitochondrial pool lest Bnip3
mediated mitophagy result in cellular death.
In order to test this hypothesis, qPCR was utilized to quantify mitochondrial
genome copy numbers through the surrogate measurement of a single mitochondrial
encoded gene, Cytochrome C Oxidase subunit 1 (Mtco1). Detection of Mtco1 relies upon
intact mitochondrial DNA (mtDNA), therefore, there would be reduced detection of
Mtco1 if alpha synuclein treatment was causing mitochondrial clearance. Importantly,
mitochondria targeted for degradation would experience rapid degradation of mtDNA
and therefore, the template used for PCR.
ddPCR was also used to quantify Beta Actin (Actb) which is a single copy gene that
is nuclearly encoded. This experiment was originally conducted to act as a surrogate
measurement of cell number. Considering that Beta Actin is a single copy gene, the copy
number from ddPCR would directly correlate to the number of cells that contributed
towards the weight of DNA in each PCR reaction. Ultimately, this was meant to be used
to normalize mtDNA copy number to cell number so that an estimate of mitochondrial
genome copy numbers per cell could be ascertained.
Materials and Methods
Cell Culture
C6 rat glioma cells were procured from the ATCC (ACTT© CCL-107™) and cultured in F12K medium containing 15% horse serum and 2.5% fetal bovine serum. Cells were
maintained in T25 flasks and utilized for experiments prior to cells reaching confluency.
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Briefly, cells were washed once with 1x HBBS and then trypsinized at 37°C until cells were
detached from the cell culture flask. Trypsin was then quenched with complete medium
and cell counts were obtained using a hemocytometer. Cells were then plated at a density
of 4x104 cells/mL per 24-well culture plate with each well containing 1 mL media. One day
after plating, cells were treated with 1 mL of 32 µg/mL alpha synuclein (rPeptide, Cat# S1001-1) in complete medium for 1 day, 2 days or 4 days in duplicate. Each time point
included duplicate control wells that received complete medium and the identical volume
of water used for alpha synuclein dosing.
DNA Extraction and Purification
Cells were harvested for DNA at the time points above using QIAgen’s QIAamp DNA
Mini Kit (Cat# 51304) per the manufacturer’s specifications and with minor modifications.
Briefly, cells were lysed in the culture dish with 200 µL Buffer AL. Following a short
incubation at RT, 200 µL PBS was pipetted to lysates. Lysates were then collected and
stored frozen at -80°C. On the day of purification, cell lysates (400 µL) were thawed at RT
and then 20 µL Proteinase K were pipetted to each lysate and mixed by pipetting. Lysates
were then incubated at 56°C for 20 minutes in a VorTemp™ 56 with 1000 rpm shaking.
Following this, 230 µL 100% EtOH was pipetted to each lysate and incubated for 5
minutes at RT after mixing by pipetting. Lysates were then pipetted to individual columns
and centrifuged at 13,000 rpm for 1 minute. The columns were then washed with 500 µL
Buffer AW1 and centrifuged as described above. Columns were then washed with 500 µL
Buffer AW2 and centrifuged as described above. Following a 1 minute centrifugation to
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remove residual wash buffer, DNA was then eluted in 100 µL nuclease-free water. Purified
DNA was then aliquoted and stored at -80°C.
DNA Quantification
DNA was quantified using the NanoDrop 8000. The mean concentration of duplicate
measurements was used for downstream applications.
2100 BioAnalyzer
DNA integrity was assessed by following the manufacturer’s specifications for the DNA
Laddering Assay.
qPCR
A 500 bp gene fragment containing both rat Cytochrome C Oxidase amplicons was
synthesized by IDT. Briefly, the DNA concentration was measured by the NanoDrop 8000
and then diluted so as to make single use aliquots that were 1e8 copies/µL. Two primer
sets for rat Cytochrome C Oxidase subunit 1 (Mtco1)(Table 1) were designed using Primer
Express (Applied Biosystems). Final PCR array conditions per well were 0.1 µM forward
and reverse primer, 1x Power SYBR™ Green PCR Master Mix (Applied Biosystems,
Cat#4367659) and 50 ng total DNA in a final reaction volume of 50 µL. Once plated and
mixed, the PCR plate was centrifuged for 5 minutes at 1500 rpm to drop the liquid down
to the bottom of the plate. The following cycling conditions were used: 50°C for 2
minutes, 95°C for 10 minutes and 50 cycles of 95°C for 10 seconds and 58°C for 60 seconds.
The qPCR was performed on an Applied Biosystems QuantStudio 7 Real-Time PCR

36

System using a ramp rate of 1.6°C/second. Data analysis was performed using the
QuantStudio 7 Real-Time PCR System software.
ddPCR
Each ddPCR reaction consisted of 0.1 µM Beta Actin (Actb) forward and reverse primer
(Table 1), 1x QX200™ ddPCR™ EvaGreen Supermix (BioRad, Cat#186-4034) and 50 ng
DNA in a final reaction volume of 20 µL. Briefly, the complete ddPCR reaction was
pipetted into the QX200 Automated Droplet Generator to generate droplets. The PCR
plate was then placed into the C1000 Touch Thermal Cycler with 96-Deep well Reaction
Module and cycled as follows: 95°C for 5 minutes and 40 cycles of 95°C for 30 seconds and
58°C for 60 seconds. The reaction products were then cooled to 4°C for 5 minutes, raised
to 90°C for 5 minutes and then lowered to 4°C with an infinite hold. Ramp rates of
2°C/second were used. Reaction products were then immediately read on the QX200
Droplet Reader. Each sample was assayed in duplicate.
Table 1. Sequences of Custom Designed Primers for qPCR and ddPCR.
Target Gene

Primer

5' - 3'

Actb

Actb-F1

GAA CCC TAA GGC CAA CCG TG

Actb-R1

TTG GCC CAA TAG AGG GGA GG

M tco1-F1

AGC AAA AGC CCA CTT TGC CA

M tco1-R1

AAG GAC GGC CGT AAG TGA GA

M tco1-F2

ATC GCA ATT CCT ACA GGC GT

M tco1-R2

TAC GAT CCC TGT TAG GCC CC

M tco1
M tco1
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Results
Cytochrome C Oxidase Subunit 1 qPCR
Treatment with alpha synuclein led to the downregulation of Bnip3, a gene whose
protein product is involved with mitophagy. In order to assess mitochondrial integrity
and quantity, two qPCR primer sets were designed against Cytochrome C Oxidase
subunit 1, a gene that is encoded by the mitochondrial genome. qPCR of mtDNA is meant
to serve as a surrogate measure of mitochondrial copy numbers through measuring
mitochondrial DNA copy numbers. C6 rat glioma cells were treated with 32 µg/mL alpha
synuclein, in duplicate cell culture wells, for 1 day, 2 days or 4 days. Purified DNA was of
acceptable concentration and purity (Figure 7) and no appreciable DNA degradation was
detected by the BioAnalyzer (Figure 8). A single standard curve was prepared for use with
both primer sets. The highest concentration started at 1e8 copies/well and was serially
diluted by 1 log increments to a final concentration of 1e2 copies/well. Primer set one
generated a standard curve (Figure 9 and Figure 10) with efficiency of 91.5% and R2=1.000
and primer set two generated a standard curve (Figure 11 and Figure 12) with efficiency of
97.5% and R2= 1.000. No template controls (NTC’s) were not detected for either primer
set. Sample quantities are the mean of two samples performed in triplicate wells and both
primer sets used the same sample DNA with weight input of 50 ng/well. For Cytochrome
C Oxidase subunit 1 primer set 1, 1 day, 2 day and 4 day samples had decreased
mitochondrial copy numbers of 39.7%, 35.4% and 30.2% (Figure 13), respectively, when
cells were treated with alpha synuclein. Mean copy numbers for the 1 day, 2 day and 4 day
control samples are 193653, 467747 and 978220, respectively. Mean copy numbers for the 1
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day, 2 day and 4 day alpha synuclein treated samples are 116689, 302326 and 682381,
respectively. For Cytochrome C Oxidase primer set 2, 1 day, 2 day and 4 day samples had
decreased mitochondrial copy numbers of 24.4%, 35.4% and 39.4% (Figure 14),
respectively, when cells were treated with alpha synuclein. Mean copy numbers for the 1
day, 2 day and 4 day control samples are 278893, 470021 and 1007939, respectively. Mean
copy numbers for the 1 day, 2 day and 4 day alpha synuclein treated samples are 210943,
303867 and 611068, respectively.
Two important observations were identified with this experiment. First,
mitochondrial genome copy numbers greatly increase over time. This result is
independent of the weight of total DNA loaded per reaction since DNA weight input per
reaction is normalized to 50 ng. Additionally, the increase in mitochondrial genome copy
number is independent of treatment with alpha synuclein.
The more critical observation from this experiment is that alpha synuclein
treatment led to loss of detection of a considerable portion of mitochondrial genomes at
each time point. This is a particularly intriguing result considering that this occurred after
only a single dose of alpha synuclein. The importance of this result will be discussed in
greater detail later in this manuscript.
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Sample ID
1 day Control_1
1 day Control_2
2 day Control_1
2 day Control_2
4 day Control_1
4 day Control_2
1 day 32 µg Alpha Synuclein_1
1 day 32 µg Alpha Synuclein_2
2 day 32 µg Alpha Synuclein_1
2 day 32 µg Alpha Synuclein_2
4 day 32 µg Alpha Synuclein_1
4 day 32 µg Alpha Synuclein_2

Conc.
(ng/µL)
39.75
38.35
35.89
37.45
88.79
90.38
98.67
96.62
173.5
193.9
214.9
214.3
33.51
34.49
33.41
33.35
88.13
93.51
88.5
93.21
176.1
194
199.1
195.6

260/280

Mean Conc.
(ng/µL)
1.78
39.1
1.75
1.66
36.7
1.66
2.01
89.6
2.04
2.14
97.6
2.11
2.13
183.7
2.13
2.12
214.6
2.1
1.87
34.0
1.92
1.82
33.4
1.83
1.94
90.8
1.99
2.02
90.9
1.98
2.08
185.1
2.14
2.15
197.4
2.15

260/230

1.92
1.87
1.82
1.86
1.96
1.95
1.99
1.97
2.03
2.01
2.01
2.02
1.86
1.87
1.81
1.81
1.99
1.97
1.96
2.01
2.02
2.02
2.02
2.02

%CV
2.54
3.01
1.26
1.48
7.85
0.20
2.04
0.13
4.19
3.67
6.84
1.25

Figure 7. NanoDrop™ 8000 DNA Concentration and Purity Data. Nanodrop™ 8000 data
shows that DNA yield is consistent between time points. DNA is highly pure and suitable
for PCR.

40

Figure 8. 2100 BioAnalyzer DNA Laddering Assay Results. Samples from left to right are:
Ladder (L), 1 day Control_1 (1), 1 day Control_2 (2), 2 day Control_1 (3), 2 day Control_2
(4), 4 day Control_1 (5), 4 day Control_2 (6), 1 day 32 µg/mL Alpha Synuclein_1 (7), 1 day
32 µg/mL Alpha Synuclein_2 (8), 2 day 32 µg/mL Alpha Synuclein_1 (9), 2 day 32 µg/mL
Alpha Synuclein_2 (10), 4 day 32 µg/mL Alpha Synuclein_1 (11) and 4 day 32 µg/mL Alpha
Synuclein_2 (12). The DNA laddering assay did not detect any discernable degradation
products.
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Figure 9. Mtco1 Primer Set 1 Standard Curve Amplification Plot. The amplification plot of
the standard curve generated using synthetic dsDNA shows high specificity and
sensitivity. The No Template Controls (NTC’s) were not amplified.
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Figure 10. Mtco1 Primer Set 1 Standard Curve Plot. The standard curve plot generated
using synthetic dsDNA is linear (R2= 1.000) and efficient (E = 91.5%).
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Figure 11. Mtco1 Primer Set 2 Standard Curve Amplification Plot. The amplification plot of
the standard curve generated using synthetic dsDNA shows high specificity and
sensitivity. The No Template Controls (NTC’s) were not amplified.
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Figure 12. Mtco1 Primer Set 2 Standard Curve Plot. The standard curve plot generated
using synthetic dsDNA is linear (R2= 1.000) and highly efficient (E = 97.5%).
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Figure 13. Mtco1 Primer Set 1 Sample Data. C6 Cells were treated with 32 µg/mL alpha
synuclein for up to 1 day, 2 days or 4 days. DNA was extracted, purified and analyzed by
qPCR. Data are represented as mean copy numbers from two cell culture wells that were
analyzed in triplicate PCR’s.
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Figure 14. Mtco1 Primer Set 2 Sample Data. C6 Cells were treated with 32 µg/mL alpha
synuclein for up to 1 day, 2 days or 4 days. DNA was extracted, purified and analyzed by
qPCR. Data are represented as mean copy numbers from two cell culture wells that were
analyzed in triplicate PCR’s.
Beta Actin ddPCR
Beta Actin ddPCR was originally conducted so as to offer a secondary means of
normalization for the mitochondrial DNA PCR data. The primary means of normalization
for PCR is nucleic acid weight input into each reaction well, however, nucleic acid weight
input only offers an estimate on how many cells contributed the nucleic acid being
analyzed. Analyzing a single copy gene, such as Beta Actin, would theoretically allow for
copies of mtDNA to be expressed as copies of mtDNA per cell.
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ddPCR was performed as previously described using 50 ng DNA per reaction and
by using the same source of DNA that was used for the mitochondrial DNA qPCR. For 1
day, 2 day and 4 day, Beta Actin detection was decreased by 25.9%, 33.8% and 21.2%
(Figure 15) respectively, when cells were treated with 32 µg/mL alpha synuclein.
This result indicates that there is consistently reduced detection of Beta Actin
DNA. Interestingly, the decreased detection of Beta Actin remains fairly consistent
throughout the time course when assessing controls and alpha synuclein treated cells
independently. This result implies that minimal degradation of nuclear DNA has
occurred and can’t be used for normalization purposes.
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Figure 15. Beta Actin ddPCR Sample Data. C6 Cells were treated with 32 µg/mL alpha
synuclein for up to 1 day, 2 days or 4 days. DNA was extracted, purified and analyzed by
ddPCR. Data are represented as mean copy numbers from two cell culture wells that were
analyzed in duplicate PCR’s.
Multiple Sequence Alignment
The amplicon sequences for Mtco1 and Beta Actin amplicons were aligned against
each other using T-Coffee software (87). Sequence alignment was conducted to assess if
any of the PCR amplicons generated in this study had any sequence homology which may
suggest that alpha synuclein is interacting with DNA in a site-specific manner and
causing DNA damage that interferes with PCR. The Mtco1 primer set 1 amplicon was
found to be 35.3% homologous to Mtco1 primer set 2 amplicon. The Mtco1 primer set 1
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amplicon was found to be 29.3% homologous to Beta Actin amplicon and the Mtco1
primer set 2 amplicon was found to be 36.3% homologous to the Beta Actin amplicon
(Figure 16).
Multiple sequence alignment indicates that there is a fair degree of homogeneity
in all aligned sequences. This offers supporting information that alpha synuclein may be
interacting with DNA in a site specific manner.

Figure 16. Multiple Sequence Alignment of PCR Amplicons. Asterisks indicate identical
nucleotides from all three amplicons.
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Discussion
The hallmark of Multiple System Atrophy is the toxic accumulation of alpha
synuclein in oligodendrocytes. Alpha synuclein found within oligodendrocytes exist as
monomers, aggregates and fibrils that are predominantly located in the cytoplasm. Of
importance is the current dogma that alpha synuclein is predominantly a neuronal
protein with minimal to no expression occurring in glial cells or in any other cell type
found in the brain. As such, MSA is currently viewed as a neuropathy whereby toxic
species of alpha synuclein are secreted into the extracellular space by neurons and
endocytosed predominantly by oligodendrocytes, presumably due to their proximity to
neurons since other glial cells uptake alpha synuclein as well.
In 2007, the Ide laboratory published Affymetrix gene expression data from a MSA
cohort study. This study was fortunate to have been conducted on pons tissue donated by
eight individuals who were diagnosed with MSA and five age matched individuals
without any known neuropathies. The resulting gene expression data that was obtained
was one of the first data sets of its kind and proved to stand the test of time having
broadly identified key features of MSA. Despite the success of that study, there are several
caveats to consider. The first is that the gene expression data set was obtained from whole
pons tissue and as such, there were numerous cell types within that tissue. The resulting
gene expression changes are not likely representative of each cell type's transcriptome,
but rather the mean gene expression change of the entire pons cell population as a whole.
Secondly, it is well known that mRNA is not stable and degradation of mRNA can begin
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occurring minutes after death. The earliest post-mortem collection of patient brain used
was 8 hours with the latest post-mortem collection at just over 32 hours.
Despite the caveats stated above, at the time, there was currently no better way to
conduct gene expression analysis on those with probable MSA, or anyone with a
neurological disease for that matter. To this end, the development of in vitro cell culture
or animal model systems are important towards elucidating disease pathogenesis since
these systems can offer end point analysis that real patients cannot realistically offer. In
addition, no patient can provide samples that show disease pathogenesis; at the time of
donation most patients have died from their disease and well after their disease has fully
progressed.
The main aim of my pilot study was to assess the use of the C6 rat glioma cell
culture system that the Ide laboratory had previously developed. This would be
accomplished by recapitulating gene expression trends from the MSA Affymetrix gene
expression data sets and then to further study how gene products could be involved in
alpha synuclein mediated pathogenesis.
The C6 rat glioma cell line has multiple phenotypes resembling oligodendrocytic
and astrocytic lineages. The C6 rat glioma cell line is highly mutagenized. For example,
Gao et al sequenced the C6 rat mitochondrial genome and found 229 indels and SNPs
which accounts for 1.40% of the total mitochondrial genome being mutated (88). Both of
these features are beneficial in a MSA cell culture system since MSA affects multiple glial
cell types and a more genetically heterogenous mitochondrial genome pool may be more
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comparable to that observed in older individuals. The main benefit of the C6 rat glioma
cell culture system, however, is that a single high concentration dose of exogenous alpha
synuclein can be applied to glial cells, thus allowing for RT-PCR analysis on how a single
dose of alpha synuclein may affect the C6 transcriptome. Ultimately, my study sought to
identify early events that may lead to MSA pathogenesis.
The C6 rat glioma cell line is an immortalized cell line that was cloned from a rat
glial tumor that had been induced by treatment with N-nitrosomethylurea which
accounts for the large number of mutations that are present in this cell line. Preliminary
data from the Ide lab suggested that baseline gene expression and mitochondrial genome
copy numbers greatly differed depending on the passage number of C6 cells utilized for
experiments. Given this characteristic of the C6 rat glioma cells, experiments were not
repeated. As such, statistics was not conducted on any data summarized in this pilot
study.
The oxidative stress PCR array was chosen as a starting point for my study due to
the well-established fact that oxidative stress is a component of the synucleinopathies.
Though it has not been ascertained as to if oxidative stress is a prerequisite for
synucleinopathy pathogenesis, alpha synuclein itself is well described to bind to
mitochondrial membranes, and at high concentrations, can even form mitochondrial
derived vesicles. This feature of alpha synuclein in of itself warranted an exploratory PCR
study into how alpha synuclein may affect genes related to oxidative stress pathways as
many of these proteins are intrinsically tied to mitochondrial health, homeostasis and
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function. Additionally, several genes that were present in the MSA Affymetrix gene
expression data set are included in the rat oxidative stress PCR array.
A Ct value cutoff of 25 was chosen so as to not include any low abundant mRNA
species as it was deemed less likely that these would provide meaningful options for
future experiments. Additionally, low abundant targets have a higher probability of
producing larger fold changes but these fold changes may not be meaningful due to low
copy numbers per cell and due to the experimental result approaching the sensitivity
limit for PCR. A fold change of 2.0 was chosen as this is industry standard for potentially
meaningful changes in gene expression.
Bnip3 was the only gene that met these criteria and importantly, this gene had
statistically significant fold changes in the MSA Affymetrix gene expression data set that
was produced in 2007 by the Ide laboratory. Therefore, total RNA from two time course
experiments was used to assess how a single 32 µg/mL alpha synuclein dose affected Bnip3
expression over the course of up to two days post treatment. ddPCR allows for the
absolute quantification of nucleic acid without the necessity of using a standard curve. It
is also highly sensitive, even when compared to other PCR techniques. Also, unlike
relative gene expression by RT-qPCR, it does not require the use of a house keeping gene
for normalization. Regardless, Hprt1 was included in the ddPCR analysis so as to offer a
secondary means to assess the quantity, quality and purity of RNA used in these
experiments. The primary means to assess RNA quantity, quality and purity was the
Nanodrop™ and the 2100 BioAnalyzer, and these instruments provided data that the RNA
was highly pure and intact. RNA quantity was comparable between samples for the short
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time course which was expected due to the short nature of the time course. For the longer
time course, total RNA yield increased over time which was expected since cells were
plated at a density that allowed them to grow to confluency in the presence of alpha
synuclein. RNA from both the short and long time course experiments was transcribed at
the same time and cDNA was analyzed on the same ddPCR plate so as to minimize inter
assay variability.
Hprt1 was not found to be consistently expressed at each individual time point
assessed, with the exception of the 48 hour time point. The ATCC notes that the C6 cell
line upregulates the S100 family members nearly 10-fold when cells approach confluency
and it is probable that Hprt1 expression follows a similar trend based on data presented in
this study. Consistent expression of Hprt1 was anticipated and shows that RNA quality,
quantity and purity were adequate for ddPCR. More importantly, the result demonstrated
that treatment with alpha synuclein did not affect Hprt1 gene expression. The result also
demonstrated that RNA was loaded equally for ddPCR.
Bnip3 gene expression marginally increased after one hour of treatment with alpha
synuclein, however, expression was consistently decreased at every other time point
assessed. Similar to Hprt1 expression, Bnip3 expression also greatly increased at the 48
hour time point and was independent of treatment with alpha synuclein. Though the
ATCC does not characterize expression of Bnip3 in C6 rat glioma cells, this gene too is
likely abundantly expressed as cells approach confluency. The largest decrease in Bnip3
expression of 29.26% occurred at the 48 hour time point which correlates to an
exceptional reduction in mRNA transcripts.
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Bnip3 is a protein that is involved with numerous cell death processes. It is
implicated in apoptosis as well as mitophagy and as such, the expression of Bnip3 is
tightly regulated and activity of Bnip3 protein is regulated by localization and post
translation modification. Interestingly, Bnip3 expression is exceptionally increased in
some tumors and silenced by methylation in others. In some tumors, Bnip3 can be highly
expressed yet little to no protein is translated. In the C6 rat glioma cell line, it is evident
that Bnip3 expression significantly increases as the cells approach confluency. This also
occurred with Hprt1 gene expression and it’s perhaps important to note that the source of
the cells, the ATCC, makes mention that certain genes are upregulated 10-fold as cells
approach confluency. A literature search yielded one paper that assessed Bnip3 protein
abundance levels by western blot, however, no other sources of literature were found to
have provided comparable data in the C6 cell line (89). Western blots were attempted in
the Ide lab but no Bnip3 signal was ever detected.
Annamarie Valenti, a previous student in the Ide lab, conducted analysis on cell
viability and cell number, using the same C6 cell culture model (90). She found no
statistical differences in cell viability for cells treated with up to 64 µg/mL alpha synuclein
vs. control. Interestingly, for the 2 day treatment, cell numbers were comparable whereas
cell numbers were substantially reduced for the 4 day, 32 µg/mL alpha synuclein
treatment; cell numbers were reduced by approximately 60%.
When considering previous data generated in the Ide laboratory, it is clear that the
substantial reduction in cell number from treatment with 32 µg/mL alpha synuclein is not
a result of cell death. As such, though the Bnip3 result is considered pilot data, the
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reduction in total number of mRNA transcripts was intriguing enough to warrant a
continuation of this study. It was surmised that a decrease in Bnip3 expression was a
response due to the aberrant activation of mitophagy. Alternatively, it was deemed
possible that other mechanisms that resulted in a clearance of mitochondria could result
in a feedback loop that decreased expression of mitophagy related genes, including Bnip3,
regardless of whether mitophagy was occurring or not. With this, the primary mechanism
of consideration was that alpha synuclein mediated clearance of mitochondria was
occurring.
Two qPCR assays were designed in order to investigate the possibility of
mitophagy occurring when cells were treated with a single dose of alpha synuclein. Two
primer sets were designed against the rat mitochondrial gene, Cytochrome C Oxidase
subunit 1 with the intention of using qPCR as a surrogate measure of mitochondrial
numbers. Both primer sets were designed so that amplicons were directly flanking each
other with the intention of detecting any differential copy numbers that might result.
This design was meant to control for other mechanisms of mitochondrial DNA
degradation, such as activation of endonucleases (91). Both qPCR results were comparable
to each other and both results indicate that there is a consistent decrease in the detection
of mtDNA copy numbers.
A third PCR assay was designed in order to ensure that total DNA was input at the
same weight and was originally meant to qualify the mitochondrial qPCR result since
both experiments used the same source of total DNA. A primer set was designed against
Beta Actin so as to assess copy numbers detected from this single copy gene. This
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methodology is often used as a surrogate measure of cell number and can provide more
accurate cell copy numbers than relying on DNA concentration alone. Interestingly,
detection of the Beta Actin gene was also decreased at two of the three time points
assessed.
The DNA concentration, purity and integrity was comparable for DNA harvested
at individual time points and minimal differences in these samples do not account for
either of the mitochondrial or Beta Actin PCR results. Furthermore, there was no
statistical difference in DNA yields at each time point. Substantial differences in
mitochondrial DNA copy numbers would not offer an appreciable difference in DNA
concentration, however, the copy number differences in Beta Actin should have been
apparent in the DNA concentration. The fact that there is no appreciable difference in
DNA concentrations implies that cells are viable, yet DNA harvested from these cells has
likely been damaged. DNA that has been damaged or nicked will not be detectable by
PCR. Though the 2100 Bioanalyzer did not detect substantial differences in DNA integrity,
it is likely that any damage is beyond the sensitivity of the 2100 Bioanalyzer to detect.
Other labs report that alpha synuclein can bind to DNA in a site specific manner (92, 93)
and can also cause DNA damage in the form of single strand breaks (94).
The main hallmark of alpha synuclein is that it is well known to bind to
membranes, and it has a propensity for binding to mitochondrial membranes in
particular. Prior studies by numerous labs have observed this feature of alpha synuclein,
however, no literature searches yielded information on how this may affect mitochondrial
genomes. As such, this may be the first PCR study to demonstrate that a single dose of
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alpha synuclein can decrease mitochondrial genome copy numbers and also have an
effect on nuclear genome integrity. Lastly, recurrent secretion of alpha synuclein by
neurons may destabilize the local cellular transcriptome in MSA patients
Conclusion
In conclusion, this study confirms the downregulation of the mitophagy related
gene, Bnip3, that was observed in the human MSA Affymetrix study that was conducted
by the Ide laboratory in 2007. Furthermore, this study further qualifies the use of the C6
rat glioma cell culture model in in vitro MSA research. Having confirmed downregulation
of the mitophagy related Bnip3 gene upon treatment with a single exogenous dose of
alpha synuclein, it was then shown that detection of the mitochondrial encoded
Cytochrome C Oxidase subunit 1 gene and the nuclearly encoded Beta Actin gene was
decreased when assessed by qPCR and ddPCR. Previous studies conducted in the Ide
laboratory demonstrate that there is no effect on cell viability when C6 rat glioma cells
are treated with 32 µg/mL alpha synuclein. Lastly, it is shown that both amplicon
sequences for Mtco1 and the Beta Actin amplicon are homologous to each other to a
moderate degree.
The results of this study demonstrate that the mitophagy related gene, Bnip3, is
downregulated in response to alpha synuclein treatment. The detection of mitochondrial
genome copy numbers is decreased when assessed by qPCR which insinuates that
mitochondrial clearance occurs when cells are exposed to a single dose of alpha
synuclein. Alternatively, alpha synuclein has been shown to bind to DNA, causing DNA
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damage that may also explain the decreased detection of mitochondrial genomes by
qPCR. Additionally, detection of the Beta Actin gene is decreased and in conjunction with
previous studies demonstrating no loss of cell viability, further suggests that transient
DNA damage has occurred in a site specific manner; widespread genomic insults would
result in loss of cell viability and proliferation. Ultimately, this study suggests that a single
treatment of alpha synuclein can affect the integrity of the mitochondrial genome pool
which holds profound implications for those with MSA and other synucleinopathies.
Future work will need to identify why there was decreased copy numbers for
mitochondrial genomes and Beta Actin as this study did not identify why there was
decreased copy numbers. Furthermore, this study did not identify if Bnip3 protein
contributes to mitophagy related processes in conjunction with alpha synuclein
treatment. Given the large body of scientific research into synucleinopathies, it is possible
that alpha synuclein itself perturbs mitochondrial homeostasis and function which
culminates in a feedback mechanism to decrease mitophagy related processes in order to
preserve the remaining mitochondrial pool.
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